Andrew J. Armstrong, MD
5 clinical trials · Sponsor
◉ Watch Andrew J. Armstrong, MD
| Record | Firm | Date |
|---|---|---|
| A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (NCT04709276) | Andrew J. Armstrong, MD | 2021-06-07 |
| A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (NCT03311555) | Andrew J. Armstrong, MD | 2018-03-28 |
| PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (NCT03179410) | Andrew J. Armstrong, MD | 2018-02-01 |
Track Andrew J. Armstrong, MD automatically
Every clearance here is in the API, with alerts when new ones post.